Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases

NCT04789668 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04789668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04789668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
January 15, 2021
Completion date
December 8, 2023
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, hematopoietic and lymphoid cell neoplasm, hormone receptor positive breast adenocarcinoma, metastatic lung non-small cell carcinoma, metastatic malignant neoplasm in the brain, metastatic malignant solid neoplasm, metastatic melanoma, metastatic triple-negative breast carcinoma, pathologic stage iv cutaneous melanoma ajcc v8, prognostic stage iv breast cancer ajcc v8, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8